The Danish Lymphoid Cancer Research (DALY-CARE) data 1 resource: the basis for developing data-driven hematology 2 Christian Brieghel^{1*}, Mikkel Werling^{1*}, Casper Møller Frederiksen¹, Mehdi Parviz^{1,2}, Caspar da Cunha-3 Bang¹, Tereza Faitova¹, Rebecca Svanberg Teglgaard^{1,3}, Noomi Vainer¹, Thomas Lacoppidan¹, Emelie 4 Rotbain^{1,4}, Rudi Agius¹, and Carsten Utoft Niemann^{1,2}. 5 1. Department of Hematology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, 6 7 Denmark 2. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark 8 3. Department of Clinical Immunology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, 9 10 Denmark. 4. Danish Cancer Institute, Copenhagen, Denmark 11 12 13 *Co-first authors Running head: The DALY-CARE data resource 14 15 16 Keywords: DALYCARE; data-driven medicine; Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma 17 (MM); lymphoma, machine learning; hematology. 18 19 Corresponding author: 20 Carsten Utoft Niemann Rigshospitalet 21 22 Department of Hematology 23 Blegdamsvej 9, building 7054 24 2100 Copenhagen Ø 25 Denmark 26 Phone: +45-35458878 27 e-mail: carsten.utoft.niemann@regionh.dk 28 Abstract word count: 148/150 29 30 Text word count: 4401/4000-4500 words 31 **Insert count**: 10/10 displays (6 figures + 4 tables) 32 Reference count: 52/60 1

33 Abstract

- 34 Lymphoid-lineage cancers (LC: lymphoma, chronic lymphocytic leukemia, multiple myeloma, and their precursors) share many
- 35 epidemiological and clinical features. To develop data-driven hematology, we gathered electronic health data and created open-
- 36 source data processing pipelines to create a comprehensive data resource for Danish LC Research (DALY-CARE) approved for
- 37 epidemiological, molecular, and data-driven research. We included all Danish adults registered with LC diagnoses since 2002
- 38 (n=65,774) and combined 10 nationwide registers, electronic health records (EHR), and laboratory data on a high-powered cloud-
- 39 computer to develop a secure research environment. We herein exemplify how DALY-CARE has been used to develop novel
- 40 prognostic markers using biobank data, real-world evidence to evaluate the efficacy of care, and medical artificial intelligence
- 41 algorithms deployed directly into EHR systems. The DALY-CARE data resource allows for development of both near real-time
- 42 decision-support tools and extrapolation of clinical trial results to clinical practice, thereby improving care for patients with LC.

43 Background & Summary

44 Lymphoma, chronic lymphocytic leukemia (CLL), plasma cell dyscrasia (PCD) and their precursors are a highly heterogenous group

- 45 of hematological malignancies in the blood, bone marrow and/or lymphoid tissues¹. They span from precursor states such as
- 46 monoclonal B-cell lymphocytosis (MBL) and monoclonal gammopathy of uncertain significance (MGUS), over indolent B-cell
- 47 lymphomas (BCL), smoldering multiple myeloma (MM) and CLL, to aggressive high-grade BCL and PCD such as amyloid light-
- 48 chain amyloidosis. Lymphoid-lineage cancers (LC) accounts for approximately 5% of all newly diagnosed cancers and more than 4%
- 49 of all cancer deaths worldwide, whereas precursors such as MGUS and MBL may be identified in 5% to 12% of healthy, older
- 50 individuals^{2,3}.
- 51 Despite the pathological, biochemical, molecular, and clinical heterogeneity of LC, they share several common features. First, all LC
- 52 derive from or are directly caused by monoclonal lymphoid-lineage expansion in blood, bone marrow and/or lymphoid tissues.
- 53 Second, they are diagnosed by either histological tissue staining, flow cytometry, and/or molecular analyses, and the diagnostic
- 54 workup typically includes biochemical blood tests, a bone marrow examination, and computer tomography (CT) or positron emission
- 55 tomography (PET)/CT imaging. Third, different LC share common epidemiology such as older age at diagnosis and male
- 56 predominance, whereas socioeconomic status and lifestyle exposures are generally not correlated with risk of developing LC. Fourth,
- 57 LC develops due to dysregulation of immune function, stimulation and signaling in conjunction with accumulation of driver
- 58 mutations⁴. Lastly, most patients with LC precursor states, CLL, indolent lymphoma or smoldering MM do not benefit from pre-
- 59 emptive treatment and are therefore followed by a watch-and-wait strategy. If or when treatment is required, it usually includes
- 60 corticosteroids, chemotherapy or immunotherapy in combination, while targeted therapies are rapidly substituting or adding to
- 61 chemoimmunotherapy combinations for most LC⁵. From an epidemiological, molecular, and data-driven perspective, the

62 commonalities between LC offer a unique opportunity for identifying common features across the different LC. This opens new

- 63 possibilities regarding modelling disease outcomes using meta-learning and federated learning along with optimized transfer of
- 64 molecular and genetic findings between the different LC. Achieving state-of-the-art accuracy of predictive models will likely require
- 65 the joint modelling of diseases i.e., including training data from patients with lymphoma and multiple myeloma may improve
- 66 predictive performance for patients with CLL.
- 67 To facilitate a shared data infrastructure to study LC, we developed the Danish LC Research (DALY-CARE) data resource allowing
- 68 for clinical epidemiology, day-to-day monitoring of clinical outcomes, omics and functional analyses of available biobank samples⁶,
- 69 and data-driven medical artificial intelligence (mAI) research⁷. Specifically, DALY-CARE has been approved by the Danish
- 70 National Ethics Committee to collect 1) biobank samples and 2) electronic health data (EHD) retrospectively and prospectively for
- 71 all Danish adult residents diagnosed with LC. DALY-CARE is approved for the study of the integrated clinicopathological profile of
- 72 LC based on medical history, clinical and paraclinical (i.e. biochemical, cellular, microbiological, pathological, radiology, molecular,
- 73 and genetic) routine data, while molecular omics (e.g. chip-array techniques, genomics, transcriptomics, proteomics, and
- 74 microbiomics) and functional analyses (e.g. immune assays, phospho-flow cytometry, in vitro drug screening and mouse xenograft

models) of adjoined biobank samples are covered by the protocol for correlations with the course of treatment and clinical outcome
 based on clinical epidemiology and data-driven mAI approaches.

77 The main driver in the recent successes of AI for image analysis and natural language processing outside of medicine is the critical 78 mass of researchers working on the same benchmarks competitively and collaboratively. This ensures a continuous improvement of 79 state-of-the-art performance on the given datasets⁸. By contrast, access to most medical data is heavily restricted. For instance, the 80 performance of prognostic models in CLL has plateaued over the last 20 years likely due to lack of (1) multiple data modalities, (2) 81 time-series modelling, and (3) a diverse set of researchers with access to the same benchmarks⁹. In turn, most mAI is developed on 82 outcomes that do not have the highest clinical impact - but instead on the restricted data sets that are easily and publicly accessible to data scientists (e.g. the MIMIC III and IV datasets)^{9,10}. With the DALY-CARE resource, we thus aim to address the aforementioned 83 84 issues of lack of multimodality, common access, and clinically valid outcomes. Within DALY-CARE, we will create benchmark 85 datasets for outcomes with high clinical impact (e.g. death, treatment response, cardiac events, adverse events and infections) and 86 provide access to the multimodal data necessary to model these. We expect this pipeline to accelerate data-driven research for 87 hematological malignancies and the subsequent development of state-of-the-art decision support tools. The DALY-CARE data 88 resource provides the setup for automatized near real-time capture and monitoring of different outcomes upon changes in clinical 89 care as well as upon deploying decision support tools, whether developed based on the DALY-CARE cohort or based on external 90 datasets.

In this paper, we provide an overview of the DALY-CARE data resource, its infrastructure, and data formats. We exemplify the
 potential of the data resource by providing examples of published studies and algorithms directly based on the DALY-CARE data
 resource.

94 Methods

95 Study population

96 We included all Danish adult residents registered with a LC diagnosis since 1 January 2002 using International Classification of

97 Diseases version 10 (ICD10; i.e. C81.x-C90.x, C91.1-C91.9, C95.1, C95.7, C95.9, D47.2, D47.9B, and E85.8A) and Systematized

98 Nomenclature of Medicine (SNOMED) codes, which could be mapped to ICD10 codes for LCs (Supplemental Table S1)¹¹. Patients

99 were identified from three data sources: 1) the Danish Clinical Quality Program – National Clinical Registries (RKKP), 2) the Danish

- 100 Health Data Authority (SDS), and 3) the EPIC®-based EHR system in eastern Denmark (Sundhedsplatformen [SP]). Nearly all
- 101 Danish patients with LC are referred to one of eight Danish hematology departments, which are placed in five Danish regions
- 102 (Supplementary Information: Hematological centers and regional assignment to patients), and the nationwide coverage for malignant
- 103 LC diagnoses within RKKP has previously been estimated to 99%¹²⁻¹⁴. The cutoff date for follow-up and inclusion of data and newly
- diagnosed patients with LC was 15 Nov 2023.

105 Data sources

- 106 EHD were primarily gathered from existing data sources as summarized in Table 1. From the RKKP registers, these include the
- 107 Danish National Lymphoma Registry (LYFO)¹⁵ since 2005, the Danish National Multiple Myeloma Database (DaMyDa)¹⁴ since
- 108 2005, and the Danish National Chronic Lymphocytic Leukemia Registry (DCLLR)¹² since 2008. Exhaustive lists of variables in the
- 109 RKKP registers are described elsewhere (Supplemental Table S2)¹⁶. From SDS starting from 2002, existing data sources included the
- 110 Register of Pharmaceutical Sales covering prescription drug data (LSR)¹⁷, the National Hospital Medication Register covering in-
- 111 hospital medication (SMR, coverage since 2004)¹⁸, the Danish National Pathology Register (PATOBANK) including pathology
- 112 notes (free text) and SNOMED codes¹⁹, the Clinical Laboratory Information System Database with routine laboratory results
- 113 (LABKA)²⁰, the Danish Register of Causes of Death (DAR)²¹, the Danish National Patient Registry (LPR) versions 1 and 3 with
- 114 diagnosis and procedure codes^{22,23}, and the Danish Cancer Registry (DCR)²⁴ (Supplemental Table S2).
- 115 We retrieved EHD from 14 modules in the EPIC® (or SP) EHR system of eastern Denmark including 1) administered medicine, 2)
- admissions (ADT), 3) active in-hospital diagnoses, 4) all test results, 5) hematology/oncology treatment plans, 6) microbiology
- 117 charts, 7) transfers between departments, 8) intensive care unit admissions, 9) medical notes (as free text), 10) prescribed medicine,
- 118 11) out- and in-patient visits and diagnoses, 12) anthropometrics, 13) a social history including smoking and alcohol consumption,
- and 13) vital signs (Supplemental Table S3; Supplementary Information: Go-live dates).
- 120 Additionally, we gathered EHD indirectly from laboratory systems at our institution. These included cleaned versions of the Danish
- 121 Microbiology Database (MiBa)²⁵ and LABKA retrieved through the Personalised Medicine of Infectious Complication in Immune
- 122 Deficiency (PERSIMUNE) covering the Capital Region of Denmark (Table 1)²⁶. In addition, we added summary reports and results
- 123 directly from the laboratory systems for routine flow cytometry analyses²⁷, immunoglobulin heavy-chain variables gene (IGHV)
- 124 analyses including stereotypic subset designation²⁸, targeted next-generation sequencing $(tNGS)^{29}$, and fluorescence in situ
- 125 hybridization (FISH) reports. Manually curated datasets collected through EHR reviews include information on patients receiving
- second line CLL treatment, patients with CLL treated with ibrutinib, patients with MM treated with daratumumab, and patients with
- 127 CLL developing Richter's transformation from previously published cohorts³⁰⁻³³.
- 128 Finally, the DALY-CARE protocol specifically allows for functional and molecular analyses including omics of biobank samples
- 129 from individuals in the cohort. For this purpose, we gathered available biobank information from four large Danish biobanks, namely
- 130 the CLL biobank, the Copenhagen Hospital Biobank, the Danish Cancer Biobank, and PERSIMUNE biobank (Table 1)³⁴. Imputed
- 131 genotypes from peripheral blood at time of first hospital blood-workup are available in 9,320 individuals (see Supplementary
- 132 Information: Future data perspectives)³⁵.
- 133

134 Ethical approvals

- 135 The DALY-CARE protocol has been approved by the Danish Health Data Authority and National Ethics Committee (approvals P-
- 136 2020-561 and 1804410, respectively). According to Danish legislation, the collection of electronic health register data is mandatory,
- and data were collected for research purposes in accordance with the approved protocol (see Supplemental Appendix). The Danish
- 138 National Ethics Committee granted an exemption for patients to provide informed consent in order to share electronic health data.
- 139 The exemption was based on the potential high impact for the patient group in question, thus considered to outweigh the issues raised
- 140 by an exemption. This exemption was also extended to allow analyses of biobank samples including extensive molecular analyses for
- 141 the retrospective part of the cohort, while for such prospective sampling, written informed consent was provided by patients to collect
- and analyze biobank samples and electronic health data.

143

144 Data Records

145 Main variables

- 146 Variables in existing data sources have been described elsewhere (Supplemental Table S2)^{12,14,15,17-21,23,25}. In short, baseline
- 147 demographic, prognostic, common biochemical, and molecular data, as well as clinical data on treatment, response, and survival are
- 148 assembled from the RKKP registers, which are kept as wide-format datasets and cleaned through protocols available in the DALY-
- 149 CARE data resource (Supplementary Information: Software). The main variables use encoding according to the Danish Medical
- 150 Classification System^a (SKS)³⁶. In brief, SKS encoding covers diagnoses, pathology, biochemistry, locations as well as surgical,
- 151 radiological and treatment procedures using ICD10, SNOMED for pathology, nomenclature property units (NPU) for laboratory,
- 152 health care provider location (SHAK), and anatomical therapeutic chemical (ATC) codes for medicine (Supplementary Information:
- 153 Codes and formats). These codes facilitate clear definitions and easy mapping of data when linking datasets in DALY-CARE
- 154 (Supplemental Table S4-S5). All diagnoses, medicine, and biochemistry across all available datasets have been gathered into
- 155 independent aggregated views.
- 156 We underscore that data do not include any sensitive information such as names, addresses, religion, ethnicity, political views,
- 157 financial data, or sexual orientation.

158

159 Database infrastructure

- 160 The DALY-CARE data resource is based on open source scalable PostgreSQL located inside a secure ISO 27001 certified private
- 161 cloud on a high-performance supercomputer at the Danish National Genome Center (NGC) research infrastructure. The server
- 162 is accessed via a Federal Information Processing Standard (FIPS) complaint virtual desktop interface (VDI) that provides full

^aSundhedsvæsenets Klassifikations System

- 163 separation between users. Built specifically with data security and privacy in mind, the platform uses 2-factor authentication (2FA)
- and layered security approach. The platform is on-premises and does not use any components that are hosted outside the
- 165 infrastructure, which ensures data security and compliance with the statutory acts³⁷.
- 166 All data are pseudonymized based on a single patient ID linked to the Danish Civil Registration System's CPR number³⁸. This allows
- 167 for unique identification of all patients and enables easy data linkage across all datasets while protecting individual patients' data
- 168 privacy (Figure 1a). All raw data are available directly in the DALY-CARE database. Newly retrieved data is quality assessed and
- 169 previous data cuts are logged to ensure the reproducibility of all studies.
- 170 The DALY-CARE server is divided into two databases with three schemas each:
- 171 1. *import*
- a. *public* contains raw data retrieved from RKKP, SDS, EHR, and PERSIMUNE.
- 173 b. *laboratory* contains data from hematological laboratories including flow cytometry, FISH, IGHV, and NGS data.
- 174 c. *lookup_tables* contain tables to map encoded data including SNOMED, SKS, ATC, ICD-10, NPU, and SHAK.
- 175 2. core
- 176 a. *public* contains cleaned versions of raw datasets and aggregated data from multiple data sources.
- 177 b. *curated* contains manually curated datasets obtained from manual EHR reviews and NGS data.
- 178 c. *lookup_tables* contain cleaned tables to map standard coding.

We created data processing pipelines and functions for loading and processing the data in both R and Python software (Figure 1b; Supplementary Information: Software). This includes pipelines that transform the raw data into a format ready to use by predictive models (feature generation), and scripts that define and extract clinical outcomes from the raw datasets. We grouped functions based on their specific purpose inside or general use outside the DALY-CARE server to allow for synergy in larger collaboratives of Danish epidemiologists and data scientists studying similar register data as well as for adaptation to similar international data. Importantly, the pipelines in R and Python software allow for direct database queries to quickly load data using indexed encoded variables (Supplemental Table S4)^{39,40}.

186

187 Biobank material

On top of the electronic register and EHR data, we also included laboratory data as indicated in Table 1. To facilitate large-scale omics studies in DALY-CARE, we searched four large Danish biobanks and identified 40,863 biobank samples either stored on different dates or collected from different tissues from 18,528 individuals. This included 21,431 samples among 9,636 patients with lymphoma (ICD10 codes C81.x-C89.x), 11,043 samples in 3,809 patient with CLL (ICD10 code C91.1), and 6,206 samples in 3,216 patients with PCD (ICD10 codes C90.0-C90.3, D47.2, and E85.8A). The different tissues included bone marrow (n=2,535), lymph

- 193 node (n=2,624), peripheral blood (n=24,068), DNA from peripheral mononuclear cells (n=2300), viably frozen cells (n=826), and
- 194 plasma (n=8,510). Most peripheral blood samples were drawn upon first hospital visit and may in most instances serve as germline
- (normal) samples. To create a large genetic repository in the future, genotyping (n>12,000), whole genome sequencing (n>2,000),
- and proteomics (n>800) is ongoing.
- 197

198 Technical validation

- 199 Patients
- We identified all adult patients with ICD10 codes or SNOMED codes that could be mapped to LC diagnoses (Supplemental Table S1 and S6). In total, we included 65,744 patients with a LC of whom 35,399 (53.8%) had more than one diagnosis: 15,838 (24.1%), 10,420 (15.8%), 5315 (8.1%), and 3826 (5.8%) patients had 2, 3, 4, and >4 different LC diagnoses, respectively. Most patients with multiple LC diagnoses were initially diagnosed with unspecified LC (e.g. C81.9, C82.9, C85.5, C85.9, and C91.9) followed by specified subclassification, whereas fewer patients had multiple diseases, progressed from precursor states to overt LC or transformed to more aggressive disease (Figure 2; Supplementary Information: Detailed patient information). The 20 most common LC diagnoses could be attributed to 62,946 patients (95.7%) and are summarized in Table 2.
- 207 At time of first LC diagnosis, the median age was 70.3 years (interquartile range [IQR] 60.7;77.9) and 56.1% were male (Table 3). 208 From the cause of death register, RKKP and EHR data, we compiled dates of last follow-up (31 Dec 2020, 15 Nov 2023, and 3 Sep 209 2023, for each source respectively) or death to calculate time from first LC diagnosis to death or end of follow-up. In 1763 (2.7%) 210 patients the last date of follow-up antedated the first diagnosis due to registration lag time. As a result, Kaplan-Meier days and 211 survival status are readily available in the DALY-CARE data resource for survival analyses. The median follow-up time was 8.5 212 years (IQR, 4.9;13.4). For the 10 most common LCs, the 5-year unadjusted OS ranged from 50.0% in MM to 74.8% in FL (Figure 3; 213 Supplemental Table S7). A detailed description of the patients and baseline characteristics is available in the Supplementary 214 Information (please see Detailed patient information). We next used clinical baseline characteristics including polypharmacy defined 215 by prescriptions in the year prior to first LC diagnosis (Supplemental Table S8) to perform multivariable Cox regression analyses in 216 LC subtypes with available information on disease-specific international prognostic indices (IPI; Supplemental Table S9). Adjusted 217 for age, sex, IPI, Charlson comorbidity index (CCI) score (2 vs >2), and polypharmacy (<5 vs \geq 5 drugs), we demonstrated an independent association with shorter OS for disease-specific IPI, CCI score, and polypharmacy (Supplemental Figure S3)^{41,42}. 218 219 However, polypharmacy intervals (0-3, 4-6, 7-9, 10-12, and >12 different ATC codes) further demonstrated a notable dose-response 220 effect on OS, which likely underscores an improved ability of prescriptions to explain the survival impact of comorbidity better than 221 ICD10 codes obtained from hospital admissions used to calculate CCI scores (Figure 4).

222 Data coverage

- 223 To avoid bias when linking different datasets, we provide an overview of coverage over time for data from RKKP, SDS, EHR, and
- 224 PERSIMUNE datasets (Figure 5 and Supplementary Figure S4). While all data are population-based, data collection was centered

around eastern Denmark and our institution in specific. We thus calculated the prevalence of CLL, DLBCL, and MM in the data available in DALY-CARE to assess regional differences, which would likely represent differences in data coverage (Figure 6). In addition to the spatial biases in the data, Figure 5 shows a clear temporal bias. Generally, more recent data has better coverage than older data: 13 out of 54 data sources plotted date back to 2002, while all 54 data sources have data available for 2019. Furthermore, difference in regional coverage over time reveal better coverage in the Capital Region for LABKA data sources (Supplemental Figures S5-S9 panels F1 and H1).

231 Previous data usage

- 232 Due to the variety of data sources and data modalities, the DALY-CARE data resource may facilitate a diverse set of research
- 233 projects. Here we highlight some of the unique possibilities of DALY-CARE by giving examples of previously published work
- 234 including use of biobank data to find novel prognostic markers, investigation of real-world evidence of different prognostic factors
- 235 influencing the efficacy of health care, and development and deployment of mAI algorithms. To avoid extreme self-citing,
- 236 publications have been summarized in Table 4.⁴³
- 237 Using biobank data, we have validated and identified molecular risk factors associated with shorter time to first treatment and disease 238 progression. In collaboration with the European Research Initiative on CLL (ERIC), we have contributed to demonstrating adverse 239 outcome for certain stereotypic B-cell receptor (BcR) subsets and identifying BcR subsets in approximately 40% of patients with 240 CLL. In other ERIC collaborations, recurrent gene mutations influence time to first treatment differently in patients with mutated and 241 unmutated IGHV status. Additionally, we have shown that recurrent gene mutations in CLL may be assigned to key signaling 242 pathways to improve prognostication of time to first treatment. We have further demonstrated that low variant allele frequency TP53 243 gene mutations do not impact overall survival time from CLL diagnosis per se, but instead have high clinical impact from time of 244 CLL treatment, whereas patients with multi-hit TP53 aberrations being treated with ibrutinib demonstrate shorter progression-free 245 survival. By accessing large Danish biobanks, we have further been able to detect CLL clones in samples decades before diagnosis of 246 CLL. In two other studies, we investigated the microbiome of CLL patients, and used fresh blood samples to demonstrate immune 247 response improvement in clinical trial patients treated with targeted therapy. In brief, these studies highlight the potential of using 248 multimodal approaches to achieve personalized medicine for patients based on for instance gene mutations, immune phenotype, and 249 microbiome analyses.
- 250 With large cohorts of patients with LC included in DALY-CARE, the data resource is highly suited for real-world evidence
- 251 epidemiological studies. By describing the Danish CLL register and validating the international prognostic index for CLL (CLL-IPI)
- in the Danish CLL population and for Binet A stage patients, we have identified variables that may supplement and improve the
- 253 predictive performance of CLL-IPI. These variables include driver mutations in cell signaling pathways, eosinophil counts,
- 254 hypogammaglobulinemia, comorbidity scores (CLL-CI), type 2 diabetes, and an index to identify patients without need of treatment
- 255 (CLL-WONT). For CLL-WONT, we subsequently showed that it was both feasible and safe to end specialized follow-up for patients

- 256 with lower risk CLL. DALY-CARE was also used to gather data from a wide range of treatment cohorts to describe real-world
- 257 outcomes upon first and second line chemoimmunotherapy and ibrutinib in CLL as well as upon daratumumab in MM. In other
- studies, we defined and assessed the risk of clinically relevant outcomes such as second primary malignancies in CLL associated with
- 259 exposure to chemoimmunotherapy, Richter's transformation associated with CLL high risk features, atrial fibrillation upon ibrutinib,
- 260 and blood stream infections in CLL and MM. Such standardized epidemiological definitions of adverse outcomes and events are
- 261 available in DALY-CARE. Prior to LC diagnosis, we have also been able to demonstrate a decade long increased prescription of
- antimicrobials, and lymphocyte slopes up until CLL diagnosis further informing disease trajectories. Finally, during the corona virus
- 263 disease pandemic, we could quickly assess and monitor mortality in a wide range of LCs, and we further demonstrated poor vaccine
- responses in CLL and better clinical outcomes during the omicron era. This underscores how frequently updated data allows for near
- real-time monitoring of large-scale real-world clinical outcomes.
- 266 We also employed DALY-CARE to develop data-driven studies using mAI. For instance, we showed that adding paraclinical
- 267 information to CLL-IPI variables improved predictive performance, whereas recurrent gene mutation information did not. This
- 268 highlights the potential within DALY-CARE to estimate which classes of variables and modelling approaches are most informative
- for a given outcome. Notably, we have developed and deployed the data driven model CLL-TIM for predicting whether patients with
- 270 newly diagnosed CLL will have an infection or will be treated within 2 years. This model was implemented into the ongoing
- 271 PreVent-ACaLL clinical trial (NCT03868722) and the EHR system of eastern Denmark, and we have shared recommendations and
- 272 considerations for easing transition from development to deployment for future mAI algorithms⁴⁴. In conclusion, these studies
- 273 highlight that DALY-CARE facilitates transformation of detailed EHD and biobank-based analyses into actionable models and
- 274 prognostic indices with direct impact on daily clinical practice.
- 275

276 Discussion

- 277 The DALY-CARE data resource is a collection of national health registries, EHRs, routine and special laboratory data as well as
- analyses from adjoined biobanks. Including more than 65,000 patients with LC, this data resource was gathered and stored on a
- 279 super-computer cloud ensuring both the data privacy and safety, storing capacity, and the processing power needed to handle
- 280 sensitive data without compromising the risk of data migration⁴⁵. Based on published studies using the DALY-CARE data resource,
- 281 we provide examples of how DALY-CARE can lead to (1) finding novel prognostic markers using biobank data, (2) using real-world
- evidence studies to evaluate the efficacy of routine health care, and (3) deploying mAI algorithms directly into EHR systems.
- 283 The DALY-CARE cohort is truly population-based as nearly all Danish adult LC patients are referred to one of eight hematological
- 284 centers and cancer registration is mandatory by law. This results in a register coverage of 99%¹³. Even so, we found large regional
- 285 disparities in the available data for patients mainly owing to EHR data being available for only two out of five Danish Regions,
- 286 covering half of the Danish population. The use of ICD10 codes upon admissions may also differ widely across institutions. This

287 skew in availability and usage could limit the scope of the possible studies or produce unintentional biases in data driven algorithms

288 if they are not accounted for. Like other EHD archives, data in DALY-CARE are affected by shifts in systems such as the transition

from LPR to LPR3 (i.e. 2 Feb 2019) or implementation of EPIC® in eastern Denmark (from May 2016 through Nov 2017;

290 Supplementary Information: Go-live dates). These time dependent changes in data and data formats are important to recognize to

avoid biases that could lead data driven algorithms astray. To this end, we focused on 1) describing when and where the data are

available and identified sub-cohorts according to ICD10 diagnoses, 2) standardization and quality control for measurements (i.e.

293 making the same measures using different units commensurable), and 3) using robust clinical definitions to calculate features based

294 on domain-knowledge such as prognostic indices.

295 By highlighting previously published work (Table 4), we hope that DALY-CARE will serve as an important first step towards

standardizing and creating similar data resources for other research groups. This would help alleviating the problem of limited

training data by enabling the use of techniques that can leverage information learned from training on other cohorts such as meta-

298 learning⁴⁶. Beyond the national generalization (e.g. SKS coding), we mapped 90% of our curated data from medicine, laboratory

299 measurements and diagnosis to OMOP standardization to facilitate international collaborations. This will also serve as a critically

300 important step for implementing state-of-the-art mAI that aggregate information across countries using federated learning.

301 Most research in mAI is almost exclusively focusing on developing novel methods and algorithms, whereas reports of deploying,

302 monitoring, improving, or maintaining existing algorithms are anecdotal^{47,48}. Outside of image analysis used for clinical care, mAI is

rarely deployed directly into clinical patient care. The DALY-CARE data resource provides real-world clinical data and is regularly

304 updated. Essential parts of the codebase are publicly available on Github and regularly updated. We believe that access to near real-

time real-world clinical data will ease the transition from development to production, aiding the issue of deploying algorithms.

306 Medical interventions for LC patients are often implemented without scientific evidence, and many interventions will never be

307 investigated in randomized clinical trials (RCT)⁴⁹. DALY-CARE provides means to qualify and inform the impact of changes in

308 health care practice that have not, cannot, and likely will never be tested sufficiently in RCTs. This is exemplified by monitoring

309 overall survival, health care utilizations and infections for patients ending specialized follow-up or receiving immunoglobulin

310 replacement therapy. Having access to large-scale multimodal data allows not only for monitoring of clinical impact after clinical

311 practice changes in management and supportive care but also when introducing novel treatments tested in RCT to RCT-ineligible

312 patients. For instance, half of all Danish patients with newly diagnosed MM did not qualify for inclusion in RCT⁵⁰, and Danish

patients on ibrutinib outside clinical trials only have a median duration to discontinuation of 3 years as compared to 7 years in clinical

314 trials^{31,50,51}.

315 Improvements in patient care is intrinsically tied to the ability to access and share data easily⁵². Here, we demonstrate how DALY-

316 CARE allows researchers to identify complex patterns across different patient cohorts and subgroups on a collaborative basis. The

317 identification of such patterns may provide new data-driven hypotheses and prognostic markers as well as inform and qualify the

- 318 impact of implemented management of LC patients, while providing the basis for development of improved decision support tools
- 319 for LC patient care. Providing the ability to share definitions, outcomes and ultimately data will allow for competitive modeling on
- 320 outcomes that would most likely increase predictive performance of prognostic models. To translate these data-driven perspectives
- 321 into benefits for patients on a national and international level, we believe it is crucial to break down the arbitrary division between
- 322 primary and secondary use of EHD. That is, utilizing daily routine EHR data and national registers for the purpose of clinical
- 323 epidemiology, precision medicine and to enrich omics analyses with clinical data.
- 324 In conclusion, we integrated real-world data from quality hematology registers, nationwide health registers, electronic health record
- data, analyses of biobank samples, and data from specialized hematological laboratories to facilitate cutting edge research in clinical
- 326 epidemiology, large-scale observational studies, omics analyses, and development of decision support tools based on machine-
- 327 learning algorithms. Capturing and utilizing routine EHD to evaluate changes in medical practice that are not based on evidence from
- 328 randomized clinical trials can now be monitored in near real-time. DALY-CARE thus paves the way for truly data-driven
- 329 hematology and provide proof-of-concept for improved data-driven health care.

330 Usage Notes

- 331 Due to pseudonymized but not fully anonymized nature of data, access to the data resource will be based on a Data Usage Agreement
- 332 (named Data Processor Agreement [DPA], see Supplemental Appendix 1 for template). The DPA will specify the analyses
- gamma performed on a collaborative basis, these analyses should be within the approved DALY-CARE protocol (Supplemental Appendix
- 2). All analyses must be performed on the DALY-CARE data resource at NGC. Except for pathology notes and medical notes,
- dummy tables are presented in Supplemental Appendix 3.

336 Code availability

- 337 The underlying code for this study is available on the DALY-CARE data resource and can be accessed on a collaborative basis on
- 338 reasonable request to the corresponding author. Essential parts of the codebase are publicly available on Github and regularly
- 339 updated.

341 Funding

- 342 The project was funded by the Alfred Benzon foundation, the Danish Cancer Society (grant R269-A15924), and the CLL-CLUE
- 343 project funded by the European Union. This work was based on data analyzed at the national infrastructure for personal medicine
- 344 hosted at the Danish National Genome Center, which is supported by the Novo Nordisk Foundation (grant agreement
- 345 NNF18SA0035348 and grant agreement NNF19SA0035486). This work was supported by Danish Data Science Academy, which is
- 346 funded by the Novo Nordisk Foundation (NNF21SA0069429) and VILLUM FONDEN (40516). The PERSIMUNE project
- 347 contributed data and achieved funding from the Danish National Research Foundation (#126). WGS is achieved through
- 348 collaboration with deCODE genetics (Reykjavík, Iceland).

349 Author contributions

- 350 C.U.N. conceived the project. C.U.N., C.B., and C.M.F. collected the data. C.M.F. created the database. C.B., C.M.F, M.W., and T.L.
- 351 created the database infrastructure. M.W. and T.L. performed data quality control. C.B. and M.W. wrote the draft manuscript. All
- authors contributed to and approved the final manuscript.

353 Acknowledgements

- 354 We would like to thank dr. Peter de Nully Brown for founding the Danish National Lymphoma Registry and leading the way for
- 355 Danish quality registers in hematology. We sincerely thank Anders Christian Riis-Jensen and Anton Kokholm Andersen from CØK
- 356 within the Capital Region of Denmark for retrieving and providing EHR data. We further thank Professor Jens Lundgren leading
- 357 PERSIMUNE for providing laboratory and microbiology data, Professor Sisse Rye Ostrowski for collaboration with the Copenhagen
- Hospital Biobank, dr. Ida Schjødt for kindly providing flow cytometry data from the Surface Marker Laboratory at Rigshospitalet, dr.
- 359 Mette Klarskov Andersen for kindly providing cytogenetics data from the Department of Clinical Genetics, Rigshospitalet, and Lone
- 360 Bredo Pedersen for performing and providing IGHV analyses from the CLL laboratory, Rigshospitalet.

361 Competing interests

- 362 CB received travel grants from Octapharma. CMF received funding from Octapharma. TL received travel grants from AbbVie
- 363 outside this study. NV received consultancy fees and funding from AstraZeneca outside of this work. ECR received consultancy fees
- 364 and/or travel grants from Abbvie, Janssen, and AstraZeneca outside of this work. CUN received research funding and/or consultancy
- 365 fees from AstraZeneca, Janssen, AbbVie, Beigene, Genmab, CSL Behring, Octapharma, Takeda, Eli Lily, MSD, and Novo Nordisk
- 366 Foundation. All other authors declare no competing interests to disclose.

367	Refer	erences							
368	1	Alaggio, R. et al. The 5th edition of the World Health Organization Classification of							
369		Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> 36 , 1720-1748 (2022).							
370		https://doi.org:10.1038/s41375-022-01620-2							
371	2	Ferlay, J. <i>et al.</i> Cancer statistics for the year 2020: An overview. <i>Int J Cancer</i> (2021).							
372		https://doi.org:10.1002/ijc.33588							
373	3	Kyle, R. A. et al. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N							
374		Engl J Med 378 , 241-249 (2018). <u>https://doi.org:10.1056/NEJMoa1709974</u>							
375	4	Niemann, C. U. & Wiestner, A. B-cell receptor signaling as a driver of lymphoma development and							
376		evolution. <i>Semin Cancer Biol</i> (2013). <u>https://doi.org:S1044-579X(13)00088-6</u> [pii]							
377	10.1016	5/j.semcancer.2013.09.001							
378	5	Greer, J. P. et al. Wintrobe's clinical hematology. Fourteenth edition edn, (Wolters Kluwer Health							
379		Pharma Solutions (Europe) Ltd., 2018).							
380	6	Hasin, Y., Seldin, M. & Lusis, A. Multi-omics approaches to disease. <i>Genome Biol</i> 18, 83 (2017).							
381		https://doi.org:10.1186/s13059-017-1215-1							
382	7	Davenport, T. & Kalakota, R. The potential for artificial intelligence in healthcare. Future Healthc J 6,							
383		94-98 (2019). <u>https://doi.org:10.7861/futurehosp.6-2-94</u>							
384	8	Russakovsky, O. et al. ImageNet Large Scale Visual Recognition Challenge. International Journal of							
385		Computer Vision 115, 211–252 (2015). https://doi.org:https://doi.org/10.1007/s11263-015-0816-y							
386	9	Agius, R., Parviz, M. & Niemann, C. U. Artificial intelligence models in chronic lymphocytic leukemia							
387		 recommendations toward state-of-the-art. Leuk Lymphoma 63, 265-278 (2022). 							
388		https://doi.org:10.1080/10428194.2021.1973672							
389	10	Johnson, A. E. <i>et al</i> . MIMIC-III, a freely accessible critical care database. <i>Sci Data</i> 3 , 160035 (2016).							
390		https://doi.org:10.1038/sdata.2016.35							
391	11	ZfKD. Zentrum für Krebsregisterdaten: Conversion table/coding manual,							
392		<https: coding="" content="" en="" krebs="" manual="" methods="" node.h<="" td="" www.krebsdaten.de=""></https:>							
393		<u>tml</u> > (
394	12	da Cunha-Bang, C. et al. The Danish National Chronic Lymphocytic Leukemia Registry. Clin							
395		Epidemiol 8, 561-565 (2016). https://doi.org:10.2147/clep.s99486							
396	13	Arboe, B. <i>et al</i> . The Danish National Lymphoma Registry: Coverage and Data Quality. <i>PLoS One</i> 11 ,							
397		e0157999 (2016). <u>https://doi.org:10.1371/journal.pone.0157999</u>							
398	14	Gimsing, P. <i>et al.</i> The Danish National Multiple Myeloma Registry. <i>Clin Epidemiol</i> 8 , 583-587 (2016).							
399		https://doi.org:10.2147/clep.s99463							
400	15	Arboe, B. <i>et al.</i> Danish National Lymphoma Registry. <i>Clin Epidemiol</i> 8 , 577-581 (2016).							
401		https://doi.org:10.214//clep.5994/0							
402	16	RKKP. Dokumentation of de nationale kliniske kvalitetsdatabaser, < <u>https://www.rkkp-</u>							
403	47	dokumentation.dk/> (2023).							
404	1/	Johannesdottir, S. A. et al. Existing data sources for clinical epidemiology: The Danish National							
405		Database of Reimbursed Prescriptions. Clin Epidemiol 4 , 303-313 (2012).							
406	10	<u>nttps://doi.org:10.214//ciep.53/58/</u>							
407	18	SDS. Sunaneasaatastyreisen: The national hospital medication register,							
408		<a> <a> 							
409	10	summeusregistre/syguomme-raegermuler-og-benandlinger/sygenusmedicinregisteret> (2023).							
410 //11	12	Registry and Data Bank Clin Enidemial 2 , 51-56 (2010), https://doi.org/10.2147/clon.c0009							
+⊥⊥ //10	20	Grann A F Frichsen R Nielsen A G Fridelay T & Thomsen P W Evicting data sources for							
712 //12	20	clinical enidemiology: The clinical laboratory information system (LABKA) research database at							
414		Aarhus University Denmark Clin Enidemiol 3 133-138 (2011) https://doi.org/10.21/7/clep.\$17901							
·									

415	21	Helweg-Larsen, K. The Danish Register of Causes of Death. <i>Scand J Public Health</i> 39 , 26-29 (2011).
416		<u>https://doi.org:10.1177/1403494811399958</u>
417	22	Lynge, E., Sandegaard, J. L. & Rebolj, M. The Danish National Patient Register. Scand J Public Health
418		39 , 30-33 (2011). <u>https://doi.org:10.1177/1403494811401482</u>
419	23	Schmidt, M. <i>et al.</i> The Danish National Patient Registry: a review of content, data quality, and
420		research potential. <i>Clin Epidemiol</i> 7 , 449-490 (2015). <u>https://doi.org:10.2147/clep.S91125</u>
421	24	Gjerstorff, M. L. The Danish Cancer Registry. <i>Scand J Public Health</i> 39 , 42-45 (2011).
422		https://doi.org:10.1177/1403494810393562
423	25	Voldstedlund, M., Haarh, M. & Molbak, K. The Danish Microbiology Database (MiBa) 2010 to 2013.
424		Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable
425		disease bulletin 19 (2014). https://doi.org:10.2807/1560-7917.es2014.19.1.20667
426	26	PERSIMUNE. PERSIMUNE: CENTRE OF EXCELLENCE FOR PERSONOALISED MEDICINE OF INFECTIOUS
427		COMPLICATIONS IN IMMUNE DEFICIENCY, <www.persimune.dk></www.persimune.dk> (2023).
428	27	van Dongen, J. J. et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric
429		immunophenotyping of normal, reactive and malignant leukocytes. <i>Leukemia</i> 26 , 1908-1975
430		(2012). https://doi.org:10.1038/leu.2012.120
431	28	Agathangelidis, A. <i>et al.</i> Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia:
432		the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL.
433		Leukemia 36 , 1961-1968 (2022). https://doi.org:10.1038/s41375-022-01604-2
434	29	Brieghel, C. et al. The Number of Signaling Pathways Altered by Driver Mutations in Chronic
435		Lymphocytic Leukemia Impacts Disease Outcome. <i>Clin Cancer Res</i> (2020).
436		https://doi.org:10.1158/1078-0432.ccr-18-4158
437	30	Vainer, N. <i>et al.</i> Real-world outcomes upon second-line treatment in patients with chronic
438		lymphocytic leukaemia. <i>Br J Haematol</i> 201 , 874-886 (2023). https://doi.org:10.1111/bjh.18715
439	31	Aarup, K. Real-World Outcome for 205 Danish Patients with Chronic Lymphocytic Leukemia Treated
440		with Ibrutinib. Ash Annual Meeting Abstract #1767 (2019).
441	32	Ben-Dali, Y. et al. Risk Factors Associated with Richter's Transformation in Patients with Chronic
442		Lymphocytic Leukemia. Ash Annual Meeting Abstract Paper abstract #1697 (2018).
443	33	Szabo, A. G. <i>et al.</i> The real-world outcomes of multiple myeloma patients treated with
444		daratumumab. PLoS One 16, e0258487 (2021). https://doi.org:10.1371/journal.pone.0258487
445	34	Laugesen, K. et al. A Review of Major Danish Biobanks: Advantages and Possibilities of Health
446		Research in Denmark. <i>Clin Epidemiol</i> 15 , 213-239 (2023). <u>https://doi.org:10.2147/clep.S392416</u>
447	35	Jensson, B. O. <i>et al.</i> Actionable Genotypes and Their Association with Life Span in Iceland. <i>N Engl J</i>
448		Med 389 , 1741-1752 (2023). <u>https://doi.org:10.1056/NEJMoa2300792</u>
449	36	Danish-Health-Data-Authority. <i>Classifications,</i>
450		https://sundhedsdatastyrelsen.dk/da/english/health_data_and_registers/classifications > (2023).
451	37	The_Danish_National_Genome_Center. Research projects on the Danish National Genome Center's
452		supercomputer, < <u>https://eng.ngc.dk/research-and-international-collaboration/research-projects-</u>
453		<u>on-the-danish-national-genome-centers-supercomputer</u> > (2024).
454	38	Pedersen, C. B. The Danish Civil Registration System. <i>Scand J Public Health</i> 39 , 22-25 (2011).
455		https://doi.org:10.1177/1403494810387965
456	39	An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-
457		analysis of individual patient data. Lancet Oncol 17, 779-790 (2016). https://doi.org:10.1016/s1470-
458		<u>2045(16)30029-8</u>
459	40	Rossum, G. v. & Drake, J. F. Python reference manual <i>Centrum voor Wiskunde en Informatica</i>
460		Amsterdam (1995).
461	41	Masnoon, N., Shakib, S., Kalisch-Ellett, L. & Caughey, G. E. What is polypharmacy? A systematic
462		review of definitions. <i>BMC Geriatr</i> 17, 230 (2017). <u>https://doi.org:10.1186/s12877-017-0621-2</u>

463	42	Quan, H. et al. Updating and validating the Charlson comorbidity index and score for risk
464		adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173, 676-
465		682 (2011). <u>https://doi.org:10.1093/aje/kwq433</u>
466	43	Van Noorden, R. & Singh Chawla, D. Hundreds of extreme self-citing scientists revealed in new
467		database. <i>Nature</i> 572 , 578-579 (2019). <u>https://doi.org:10.1038/d41586-019-02479-7</u>
468	44	Agius, R. et al. Implementation of the CLL Treatment Infection Model Adjoined to an Electronic
469		Health Record System - Guidelines for Practical Implementation of Data-Driven Models. Preprints
470		with the Lancet. (2023). < <u>https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4555192</u> >.
471	45	Zhang, J. et al. Mapping and evaluating national data flows: transparency, privacy, and guiding
472		infrastructural transformation. Lancet Digit Health 5, e737-e748 (2023).
473		https://doi.org:10.1016/s2589-7500(23)00157-7
474	46	Zhang, X. S., Tang, F., Dodge, H. H., Zhou, J. & Wang, F. MetaPred: Meta-Learning for Clinical Risk
475		Prediction with Limited Patient Electronic Health Records. <i>Kdd</i> 2019 , 2487-2495 (2019).
476		<u>https://doi.org:10.1145/3292500.3330779</u>
477	47	Seneviratne, M. G., Shah, N. H. & Chu, L. Bridging the implementation gap of machine learning in
478		healthcare. <i>BMJ Innovations</i> 6, 45-47 (2020). <u>https://doi.org:doi:10.1136/bmjinnov-2019-000359</u>
479	48	Tomašev, N. et al. Use of deep learning to develop continuous-risk models for adverse event
480		prediction from electronic health records. <i>Nature protocols</i> 16 , 2765-2787 (2021).
481		<u>https://doi.org:10.1038/s41596-021-00513-5</u>
482	49	Djulbegovic, B. A framework to bridge the gaps between evidence-based medicine, health
483		outcomes, and improvement and implementation science. J Oncol Pract 10, 200-202 (2014).
484		https://doi.org:10.1200/jop.2013.001364
485	50	Klausen, T. W. <i>et al.</i> The majority of newly diagnosed myeloma patients do not fulfill the inclusion
486		criteria in clinical phase III trials. <i>Leukemia</i> 33, 546-549 (2019). <u>https://doi.org:10.1038/s41375-018-</u>
487		<u>0272-0</u>
488	51	Aarup, K. <i>et al.</i> Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated
489		with ibrutinib. <i>Eur J Haematol</i> 105 , 646-654 (2020). <u>https://doi.org:10.1111/ejh.13499</u>
490	52	Bauchner, H., McDermott, M. M. & Butte, A. J. Data Sharing Enters a New Era. Ann Intern Med 176,
491		400-401 (2023). <u>https://doi.org:10.7326/m22-3479</u>

492

493 Tables

- 494 Please see separate excel files.
- 495 Table 1. Overview of datasets in the DALY-CARE data resource
- Table 2. Most common lymphoid-lineage cancer disorders in the DALY-CARE data resource.
- 497 Table 3. Patient characteristics.
- **498** Table 4. DALY-CARE data resource usage.



500 Figures and legends

502 Figure 1. Schematic overview of the Danish Lymphoid Cancer Research (DALY-CARE) data resource. Data 503 from various sources including Danish nationwide registers, hematological quality registers, electronic 504 health record data, and hematological laboratories may be linked using a single pseudonymized patient ID 505 (a). Hosted on the Danish National Genome Center high-performance computer (HPC) cloud, all data are placed in a PostgreSQL database accessed by 2-factor authentication (2FA) and loaded via R or Python 506 software (b). Database queries and pipelines to load and transform data based on encoded data (e.g. 507 508 patient ID, international classification of disease version 10 [ICD10], nomenclature property units [NPU], 509 and anatomical therapeutic chemical [ATC]) facilitate easy data transformation commonly used for survival 510 analyses and data-driven research (c).



511

512 Figure 2. Correlations between lymphoid-lineage cancer (LC) ICD10 diagnoses shown as pairwise Fisher's 513 exact tests. The log odds ratio is indicated when the false detection rate (FDR) was above 0.1. ICD10 pairs 514 with an FDR ≥ 0.1 are indicated in white. B cell lymphoma, BCL; chronic lymphocytic leukemia, CLL; diffuse 515 large B cell lymphoma, DLBCL; extranodal marginal zone lymphoma, EMZL; follicular lymphoma, FL; Hodgkin lymphoma, HL; lymphoid leukemia, LL; lymphoplasmacytic lymphoma, LPL; mantle cell lymphoma, 516 517 MCL; monoclonal gammopathy of uncertain significance, MGUS; multiple myeloma, MM; monoclonal B-cell 518 lymphocytosis, MBL; non-Hodgkin lymphoma, NHL; nodular sclerosis, ns; not otherwise specified, NOS; 519 small lymphocytic lymphoma, SLL; unspecified, UNS; Waldenström macroglobulinemia, WM.



521

522 Figure 3. Unadjusted overall survival in 10 LC diagnoses. Burkitt lymphoma, BL; classical Hodgkin

523 lymphoma, cHL; chronic lymphocytic leukemia, CLL; diffuse large B cell lymphoma, DLBCL; follicular

- 524 lymphoma, FL; lymphoplasmacytic lymphoma, LPL; mantle cell lymphoma, MCL; multiple myeloma, MM;
- 525 marginal zone lymphoma, MZL; not otherwise specified, NOS; small lymphocytic lymphoma, SLL.

526

All				H	azard	ratio							
	Age	(N=28655)	(2.1 ^{1.1} (2.1-1.1)										<0.001 ***
- 1	Sex	F (N=22666)	reference										
		14 (N=25889)	a 1.1.0										<0.001 ***
- 1	IPI	10m 11-62231	reference		i								
1		intermediate (N=23923)	(2.4+1.6)						-				<0.001 ***
- 1		idgh (N=8519)	(2.0-2.2)								H	-	<0.001
	ATC	(11-8848)	reference	ė	í.								
- 1		4-6 (N=7039)	a 1-1 21		-	-							<0.001
		719-5504)	(1.2.1.3)			-							<0.001 ***
- 1		10-12	(2.4-2.6)				4	-	-				«0.001 ····
		>12 (N=3790)	(1.6-2.0)							-	•		+0.001 ***
1	cci	(#=28655)	a.1.1.1.1										<0.001 ***
	# Events: A/C: 2571	13776: Global p-vi 46.39; Concordanc	elue (Log-Rank) e Index: 0.72	. <.003		12	1	4	1.6	18	2	22	2.4

HL		ł	Hazard I	atio			
IPS	Low (N=1122)	reference					
	())=1003)	13.2.4.7)				-	
ATC	0-3 (N=978)	teference	•				
	4-6 (N=897)	a.1.3					0.014 *
	7-9 (W=310)	12.4.2.3)			•		×0.003
	${}^{10-12}_{(n=164)}$	a33.7			i	.	~0.003
	(N=176)	(2.8.2)			,	-	- <0.002 ***
cci	(N=2128)	(2.0-2.1)	-				0.003
# Events: AIC: 8637	634: Global p-val 08: Concordance	ue (Log-Rank): < 001 Index: 0.74	1	15	2 25	3 35 4	4.5 5 5.5

DLBCL			Hazard ratio					
Sex	р (N=3682)	reference						
	M (N=4774)	(1.1-1.2)	-					<0.001 **
R-IP1	10W (N=748)	reference						
	interrediate (N=3854)	(2.5-3.2)		-				<0.001 **
	High (N=3824)	4.8 (4.2 - 5.7)				-	-	<0.001 **
ATC	0-3 (N=2563)	reference	•					
	4-6 (N=2083)	(1.2-1.4)	- -					<0.001 **
	7-9 (N=16-79)	(1.4-1.7)						<0.001 **
	(N=1049)	(1.7 - 2.2)	-	-				<0.001 **
	≥12 (N=1112)	(2.2.2.7)						<0.001 **
cci	(N=8456)	(1.0-1.1)						<0.001 **
 Events: 43 AIC: 72378.3 	57: Global p-vak 3: Concordance	ve (Log-Rank): < 00 Index: 0.67	a	2	3	4	5	6 7

			Hazard ratio		
Sex	r (N=2286)	roference	i 🛉		
	M (N=2268)	(2.2.2.5)			<0.001 ·
FLIP12	(N=744) reference				
	(N=2673)	(2.2.3.2)			<0.001
	High (N=21.97)	13.0 - 5.71			■ <0.001 *
ATC	0-3 (N=2607)	reference			
	(N=1112)	(7.2+2.6)			<0.002
	7.9 (N=755)	(2.6.2.1)	-	-	<0.001 *
	10-12 (N=434)	(1.8.3.5)			<0.001 -
	>12 (N=446)	(2 7-3.7)		⊷ ∎ →	40.002 •
cci	(N=4554)	(2.0-2.1)			0.002
# Events: 1 AIC: 26000	1706; Global p-val ; Concordance Ind	ve (Log-Ranks: <.00 ex: 0.7	1		



ZL			Hazard	ratio	D						
Sex	r (N=1075)	reference									
	M (N=898)	(2.35-1.8)	1			•					
MALT-IPI	10 A 331	reference									
	(n=\$14)	(2.51.9 (2.51.2.4)			-						<0.001
	199h (N=720)	(2.78:24.5)									<0.001
ATC	0-3 (N=602)	reference									
	4-6 (N=482)	(0.96 . 1.5)	-		-						0.121
	7-9	(2.23 - 2.0)		+							~0.001 ~~
	10-13 (N=248)	(1.70 . 2.7)				-	-				0.001
	>12 (N=252)	(2.08.3.2.1)				-		- 1			40.002 ····
cci	(N=1973)	(2.16-1.3)		-							<0.001 ····
# Events: 76 AIC: 16522.2	16: Giobat p-val 1: Concordance	ue (Log-Rank): <.003 Index: 0.7			1.5	7	2.5	3	3.5	4.4	5 5 5 5

۲L			Hazard	ratio					
Sex	(N=603)	reference							
	M (N=981)	(2.1-3.0)	-	•				a	002 **
IPSSWM	(N=424)	reference							
	N=763)	(1. 7. 2.8)		+					0.002 **
	High (N=397)	(3.2 - 5.3)				-	-		
ATC	0-3 (N=524)	reference							
	4.6 (N=399)	(2.0-2.7)						Ø.	044 *
	7-9 (N=296)	(2 3 2 1)		-					0.001 ***
	10-12 (N=192)	a7-2.91		+				-	0.001
	×12 (N=183)	(2.1-2.2)							0.001 ***
cci	(N=1584)	(1.2.+1.3)		•					100.03
# Events: 56 AIC: 7246.91	61; Global p-valu 7; Concordance in	e (Log-Rank): <002 ndex: 0.7			2	3	4	5	6

MCL			Hazard ra	tio					
Sex	₹ (N=437)	reference							
	M (N=899)	(1.1-1.5)		-					0.005 **
MIPI	182=218)	reference	i i i						
	Intermediate (N=J46)	(1.4-2.7)			—				<0.002 ***
	1800 2N 4672)	4.4 (2.2 - 5.8)						-	- <0.002 ····
ATC	0-3 (N=d50)	reference							
	4-6 (N=327)	(1.1+1.6)		H-1					0.004 **
	7-9	(1.2 - 1.0)	- i						<0.002 ***
	10-12 (N=245)	(1.4.2.4)			-				<0.002 ***
	(n=257)	(1.9-3.0)		-		1			<0.001 •••
cci	(N=2334)	(1.0-1.1)							0.036 *
# Events: AIC: 9386	743: Global p-value 74: Coricordance Ir	t (Log-Rank): <.00 ч/ек: 0.68	1			5	4		6 7

м	н	lazard ratio					
Age	(N=E701) (1.03-1.1)	-					<0.001 ***
Sex	P (N=296)) reference	- .					
	M=2740) (1.19-31.4)		•				<0.002 ***
8-ISS	(W=1737) reference						
	(n=4139) (1.71 - 2.0)	1		•			<0.001 ***
	High (N=#25) (2.58-3.2)				+	-	• <0.002 ····
ATC	0-3 (N=1+30) reference						
	(N=1592) (0.96-1.2)						0.242
	719=1453) (1.03-1.1.2)						0.022 -
	(N=371) (1.15-1.4)		-				<0.002 ····
	>12 (N=1235) (1.45-1.8)						<0.001 ***
ca	(N=6701) (1.03-1.1)						<0.001 ····
# Events: 4 AJC: 63048	1017; Glubal p-value (Log-Rank): <.001 43; Concordance Index: 0.7	i	1.5	2	2.5	3	3.5

- 529 Figure 4. Multivariable analyses on age, sex, disease-specific international prognostic index (IPI), the number of anatomical therapeutic chemical (ATC)
- 530 codes from prescription in the year prior to diagnosis, and Charlson comorbidity index (CCI) score in all disease, classical Hodgkin lymphoma (cHL),
- 531 diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), chronic lymphocytic
- 532 leukemia (CLL), lymphoplasmacytic lymphoma (LPL), and multiple myeloma (MM). In the pooled analysis of all disease, CLL-IPI high and very high risk
- 533 grouped into high IPI and revised international staging system (R-ISS) I, II, and III were labeled low, intermediate, and high risk, respectively.



534



536 hematological quality registers are wide format datasets, where data are typically entered upon

537 diagnosis/registration, upon treatment, relapse, and follow-up (a-c). SDS LPR register was replaced by LPR3

in Feb 2019 (d, g). Epikur (prescriptions), LABKA (blood tests), and PATOBANK (pathology requisitions) were independent of this update (e, f, h). We underscore that similar data from different data sources may have

540 different time coverage (f, i). The electronic health record system of eastern Denmark (SP) went live in Mar

541 2016 (j). Even so, medical notes antedating go-live dates from the previous EHR system were imported and

542 are available as historic notes (k). A steadily increasing number of antimicrobial analyses was observed (l).

543 Each panel shows the time coverage of a single dataset (a-l). Note that the y-axis shows the number of

observations in three-month intervals on a log-scale. Lines above bins represent kernel density estimates of

545 the counts.



546

547 Figure 6. Number of patients per 100,000 residents in a) chronic lymphocytic leukemia (CLL), b) diffuse

548 large B-cell lymphoma (DLBCL), and c) multiple myeloma (MM). Numbers included all patients in the DALY-

549 CARE data resource regardless vital status.



ID	Key	Value	Source
1001	HGB 12		LAB
1001	PS	0	LYFO
1002	IGHV	U	CLL
1003	Systolic	112	VITAL
1003	ATC	L01E	RX

Correlogram of LC diagnoses





Ш				Hazard	ratio					
	Age	(N=28655)	(1.1-1.1)	•						<0.001 ***
	Sex	F (N=12666)	reference							
		M (N=15989)	1.3 (1.3 - 1.4)			-				<0.001 ***
	IPI	Low (N=6213)	reference							
1		Intermediate (N=13923)	1.5 (1.4 - 1.6)			-	•			<0.001 ***
		High (N=8519)	2.1 (2.0 - 2.2)							<0.001 ***
	АТС	0-3 (N=8848)	reference							
		4-6 (N=7039)	(1.1 - 1.2)		4					<0.001 ***
		7-9 (N=5504)	(1.2 - 1.3)							<0.001 ***
		10-12 (N=3474)	1.5 (1.4 - 1.6)	1						<0.001 ***
		>12 (N=3790)	1.9 (1.8 - 2.0)				F	-		<0.001 ***
	ссі	(N=28655)	$(1.1^{1.1}, 1.1)$							<0.001 ***
	# Events: 1377 AIC: 257146.39	76; Global p-v. 9; Concordanc	alue (Log-Rank): < e Index: 0.72	001	12 1	1 1	6 1	8 2	2.2	2.4

Δ

FL				Hazaro	lazard ratio						
				-							
	Sex	F (N=2286)	reference	ė							
		M (N=2268)	$ \begin{array}{r} 1.4 \\ (1.2 - 1.5) \end{array} $		i ⊢∎ ⊣				<0.001 ***		
	FLIP12	Low (N=744)	reference	ļ							
		Intermediate (N=2673)	2.6 (2.2 • 3.2)						<0.001 ***		
		High (N=1137)	4.7 (3.8 - 5.7)				-		<0.001 ***		
	АТС	0-3 (N=1807)	reference	ė							
		4-6 (N=1112)	1.4 (1.2 - 1.6)		⊢∎⊣				<0.001 ***		
		7-9 (N=755)	1.8 (1.6 - 2.1)		⊢ ∎-	-1			<0.001 ***		
		10-12 (N=434)	2.1 (1.8 - 2.5)						<0.001 ***		
		>12 (N=446)	3.2 (2.7 - 3.7)			F	▦ᢇ		<0.001 ***		
	ссі	(N=4554)	(1.0 - 1.1)						0.002 **		
	# Events: 1706 AIC: 26000; Cor	; Global p-valu ncordance Inde	ue (Log-Rank): <.00 ex: 0.7	01		2	3 /	5	6 7		

CL	.L			Hazaro	l ratio					
	Sex	F (N=1622)	reference							
		M (N=2429)	(1.2 - 1.5)		·					<0.001 ***
	CLL-IPI	Low (N=1903)	reference							
j		Intermediate (N=1194)	(1.5 - 2.0)				-			<0.001 ***
		High (N=954)	2.9 (2.6 - 3.3)					-		<0.001 ***
	АТС	0-3 (N=1462)	reference							
j		4-6 (N=1045)	(1.1 - 1.5)	F	-					<0.001 ***
		7-9 (N=704)	$ \begin{array}{r} 1.5 \\ (1.3 - 1.8) \end{array} $							<0.001 ***
		$^{10-12}_{(N=435)}$	(1.8 - 2.5)			H	-			<0.001 ***
		>12 (N=405)	2.8 (2.4 - 3.3)							<0.001 ***
	ссі	(N=4051)	(1.1 - 1.1)	-					-	=0.001 ***
	# Events: 1606 AIC: 24032.01;	; Global p-val Concordance	ue (Log-Rank): <.0 Index: 0.68	01	1	5	2	2.5 3	3	5

c	cHL Ha		Hazard ra	izard ratio					
	IPS	Low (N=1122)	reference						
		High (N=1003)	3.9 (3.2 - 4.7)					── <0.001 ***	
	ATC	0-3 (N=978)	reference	-					
		4-6 (N=497)	(1.1 · 1.7)	—				0.014 *	
		7-9 (N=310)	1.8 (1.4 - 2.3)		ا ا			<0.001 ***	
		10-12 (N=164)	2.9 (2.2 - 3.7)				 ,	<0.001 ***	
		>12 (N=176)	3.3 (2.6 - 4.2)			H		H <0.001 ***	
	ссі	(N=2125)	$(1.0^{1.1}_{-1.1})$	H				0.003 **	
	# Events: 634 AIC: 8647.08;	; Global p-valu Concordance	ie (Log-Rank): <.001 Index: 0.74		1.5	2 2.5	3 3.5 4	4.5 5 5.5	

IZL			Haza	rd ratio	þ				
Sex	F (N=1075)	reference		L					
	M (N=898)	(1.35 - 1.8)		Ĥ					<0.001 ***
MALT-IPI	Low (N=439)	reference		I					
	Intermediat (N=814)	e 1.9 (1.51 - 2.4)				-	•		<0.001 ***
	High (N=720)	(2.79 - 4.5)					-	-	
АТС	0-3 (N=602)	reference	ļ						
	4-6 (N=481)	(0.96 - 1.5)	r.	-	-				0.121
	7-9 (N=390)	(1.29 - 2.0)		F	-	-			<0.001 ***
	10-12 (N=248)	(1.70 - 2.7)				-			<0.001 ***
	>12 (N=252)	(2.00 - 3.1)					-	e i	<0.001 ***
ссі	(N=1973)	(1.16 - 1.3)		H					<0.001 ***
# Events: 786; AIC: 10522.2;	: Global p-vali Concordance	ue (Log-Rank): < Index: 0.7	.001		1.5	2	2.5 3	3.5 4	4.5 5 5.5

PL			Hazaro	d ratio				
			:					
Sex	F (N=603)	reference	, i					
	M (N=981)	$(1.1 \cdot 1.6)^{1.3}$	F					0.002 **
IPSSWM	Low (N=424)	reference	ļ					
	Intermediate (N=763)	(1.7 • 2.8)		-	-	-		<0.001 ***
	High (N=397)	$\begin{array}{c} 4.1\\(3.2-5.3)\end{array}$					-	→ <0.001 ***
АТС	0-3 (N=514)	reference	ė					
	4-6 (N=399)	1.3 (1.0 • 1.7)						0.044 *
	7-9 (N=296)	$(1.3 \cdot 2.1)^{1.6}$		·				<0.001 ***
	10-12 (N=192)	(1.7 - 2.9)		F	-	-		<0.001 ***
	>12 (N=183)	2.4 (1.8 - 3.2)						<0.001 ***
ссі	(N=1584)	$(1.2 \cdot 1.3)$		⊢∎ -1				<0.001 ***
# Events: 56 AIC: 7246.97	Events: 561; Global p-value (Log-Rank): <.001 C: 7246.97; Concordance Index: 0.7				2	3	4	5 6

DLBCL			Hazard rati	ю				
Sex	F (N=3682)	reference						
	M (N=4774)	1.2 (1.1 - 1.2)	i∰ i					<0.001 **
R-IPI	Low (N=748)	reference						
	Intermediate (N=3894)	(2.3 - 3.2)				-1		<0.001 **
	High (N=3814)	(4.1 - 5.7)						┥ <0.001 **
ATC	0-3 (N=2563)	reference						
	4-6 (N=2083)	(1.2 · 1.4)	·					<0.001 **
	7-9 (N=1649)	1.5 (1.4 - 1.7)	H	-				<0.001 **
	10-12 (N=1049)	1.9 (1.7 - 2.1)		⊢∎-	-			<0.001 **
	>12 (N=1112)	(2.2 · 2.7)			⊢∎⊣			<0.001 **
ссі	(N=8456)	(1.0 - 1.1)						<0.001 **
# Events: 435 AIC: 72378.33,	7; Global p-valu ; Concordance	ve (Log-Rank): <.00. Index: 0.67		2		3	4 5	6 7

М	CL			Hazard rat	io		
Ì	Sex	F (N=437)	reference				
1		M (N=899)	(1.1 - 1.5)	·	í .		0.005 **
	МІРІ	Low (N=218)	reference				
		Intermediate (N=446)	(1.4 - 2.7)		-	-	<0.001 **
		High (N=672)	4.4 (3.3 - 5.8)				<0.001 **
	АТС	0-3 (N=450)	reference	÷.			
		4-6 (N=327)	(1.1-1.6)		-		0.004 **
		7-9 (N=257)	(1.2 - 1.8)				<0.001 **
		10-12 (N=145)	1.8 (1.4 - 2.4)				<0.001 **
		>12 (N=157)	(1.9 - 3.0)				<0.001 **
	ссі	(N=1336)	(1.0 - 1.1)	.			0.036 *
	# Events: 74 AIC: 9486.74	13; Giobal p-value I; Concordance Ir	e (Log-Rank): <.00 dex: 0.68	21			

MM			Hazard rat	io			
Age	(N=6701)	(1.05 - 1.1)					<0.001 ***
Sex	F (N=2961)	reference					
	M (N=3740)	(1.19 - 1.4)		-			<0.001 ***
R-ISS	Low (N=1737)	reference	, i				
	Intermedia (N=4139)	te 1.9 (1.71 - 2.0)		μ	.		<0.001 ***
	High (N=825)	2.9 (2.58 - 3.2)					<0.001 ***
ATC	0-3 (N=1450)	reference					
	4-6 (N=1592)	(0.96 - 1.2)					0.242
	7-9 (N=1453)	$(1.02 \cdot 1.2)$		-			0.022 *
	10-12 (N=971)	(1.16 - 1.4)	- I				<0.001 ***
	>12 (N=1235)	(1.45 - 1.8)			í.		<0.001 ***
ссі	(N=6701)	$(1.03 \cdot 1.1)$					<0.001 ***
# Events: 40 AIC: 63048.4	17; Global p-v 3; Concordanc	alue (Log-Rank): < :e Index: 0.7	1	1.5	2 2.	5 3	3.5

